Object. The purpose of this study was to assess outcomes of Gamma Knife surgery (GKS) as a second treatment for recurrent or residual trigeminal neuralgia (TN) after failure of 3 initial procedures: microvascular decompression (MVD), GKS, and percutaneous radiofrequency rhizotomy (PRR).
T rigeminal neuralgia is usually treated with MVD, PRR, or GKS when medications fail. However, refractory pain is often difficult to control after the first treatment. According to the literature, the recurrence rates after these 3 procedures also differ and vary from 6% to 57%. 2, 5, 7, 10, 20, 23 Broggi et al. 5 reported a recurrence rate of 18.1% after PRR within 3 years. Taha et al. 23 reported a recurrence rate of 25% 14 years after PRR. In an MVD group, Baker et al. 2 noted 11% of patients underwent a second operation for recurrence after a 10-year follow-up. In our previous report, 10 we showed that 22.4% of patients had recurrent or residual pain after GKS at a mean follow-up of 5.6 years. Dhople et al. 7 reported that 19% of patients had pain recurrence as a long-term result. Sanchez-Mejia et al. 20 found in their series that the retreatment rate was 20% after MVD, 6% after GKS, and 57% after PRR.
Some patients with residual or recurrent pain require further therapy, be it radiosurgery or other methods. Gamma Knife surgery is used to manage recurrent facial pain or pain that is not adequately controlled following an initial procedure. Previous studies on the use of GKS for recurrent pain have referred to results after 1 or multiple prior surgeries, but outcomes are often compared by treating pain recurrence after single and multiple sur-geries as being the same condition. We report results for patients who only underwent a single procedure, including GKS as a primary treatment, for residual or recurrent trigeminal neuralgia, and our study also includes a substantially longer follow-up time than other studies.
Methods

Patient Population
Between 1999 and 2008, 65 patients who experienced recurrent or residual idiopathic TN following an initial procedure underwent radiosurgery performed using the Leksell Gamma Knife. All 65 patients had undergone previous medical procedures that failed to achieve the desired effect: 27 patients (42%) had undergone MVD, 8 (12%) had undergone PRR, and 30 (46%) had undergone GKS as an initial procedure. Sixty patients had typical TN and 5 patients had atypical TN, including 2 patients in the initial GKS group, 2 in the initial MVD group, and 1 in the initial PRR group.
The median interval between the initial procedure and GKS was 25 months (range 2-192 months). The median follow-up period after GKS was 64 months (range 18-132 months). The median age of patients at the time of radiosurgery was 61 years (range 34-84 years). All patients provided informed consent before treatment and had completed clinical follow-up for their initial treatment. The characteristics of these 65 patients, stratified by the 3 initial treatment groups, are summarized in Table 1 .
Radiosurgical Procedure
All patients were treated using the Leksell Gamma Knife model B (Elekta AB). As part of the GKS procedure, patients received a local anesthetic agent to facilitate pain-free mounting of the stereotactic frame. Targeting was based on an MR imaging treatment plan using a 1-mm axial slice interval with no gap. The designated target was the entry zone of the trigeminal nerve, immediately adjacent to the pons. During the first GKS performed in the initial MVD and initial PRR groups, every patient received a single isocenter radiation dose, which ranged from 70 to 90 Gy (mean 77.4 Gy) and was delivered to the 100% dose point using a 4-mm collimator.
At the time of the second GKS for the initial GKS group, every patient was treated with a maximum dose ranging between 35 and 80 Gy (mean 49 Gy), which encompassed the periphery of the same designated treatment volume as the first target. When we first began to deliver repeat GKS, we selected the radiation dose used at the first procedure but observed a high rate of facial numbness in our patients. We attributed this numbness to a relatively high dosage directed to the same target location. In an attempt to decrease the incidence of facial numbness, we reduced the dose in later repeat treatments to 35-50 Gy while continuing to target the same location. All patients in this group received a total dose of 110 to 152 Gy (mean 129 Gy).
At the initial failed GKS procedure, we positioned the isocenter 2.5-4 mm anterior to the junction of the trigeminal nerve and brainstem, so that the brainstem surface received no more than a 20% isodose in 59 patients, and caution was taken during targeting to prevent the pons and brainstem from receiving more than 15 Gy at the margin (Fig. 1) . Only 6 patients with a narrow cistern space (that is, a short trigeminal entry) in the posterior fossa received a 30% isodose. At the second procedure, we positioned the target at the same location as that used during the first treatment.
Evaluation of Outcomes
We divided clinical pain outcomes into 5 categories using the BNI pain intensity scale: Score I, no pain with no medication; Score II, occasional pain but no medication; Score IIIa, no pain and continued use of medication; Score IIIb, some pain adequately controlled by medication; Score IV, pain improved but not adequately controlled by medication; and Score V, no pain relief. 22 Our criteria for improvement included a reduction in both the frequency and severity of pain. Successful pain control was defined as Scores I-IIIb.
Severity of facial numbness was divided according to the BNI 4-point facial numbness scale: Score I, no facial numbness; Score II, mild facial numbness; Score III, facial numbness somewhat bothersome; and Score IV, facial numbness, very bothersome. Patients were also asked about corneal anesthesia and mastication complications.
Statistical Analysis
We used a chi-square test to evaluate the correlation between the total radiation dose and pain relief or sensory change and the Fisher exact test for pain outcome in the 3 initial treatment groups.
Results
Pain outcomes after GKS for recurrent TN were BNI Score I in 22 patients (34%), Score II in 11 patients (17%), Score IIIa in 4 patients (6%), and Score IIIb in 5 patients (8%) ( Table 1) . At a median follow-up time of 64 months, 65% of patients reported successful pain control. At the 1-, 2-, and 3-year follow-up examinations, 74%, 71%, and 66% of patients, respectively, experienced successful pain control. Pain relief was not significantly better in the initial MVD group than in the initial GKS and initial PRR groups (74% vs 59% and 50%, respectively; p = 0.342). The rates of pain control with or without medication are shown in Fig. 2 .
Twenty-three patients (35%) still had intractable pain. Eight patients with recurrent facial pain underwent MVD at a median follow-up of 6 months (range 3-27 months) after repeat GKS; 7 of these patients experienced complete pain relief. Twelve patients with recurrent facial pain underwent repeat GKS. In this subgroup, the median time of recurrence was 8 months (range 3-48 months). At a later follow-up, 8 (67%) of the 12 patients experienced successful pain control (Table 1) .
Complications were limited to the onset of new facial numbness in 17 patients (26%): 5 (19%) in the initial MVD group, 11 (37%) in the initial GKS group, and 1 (12%) in the initial PRR group (Table 1) . There was no significant difference in new facial numbness among the 3 groups (p = 0.24), but the initial GKS group tended to have a higher chance of facial sensory loss (Table 1) . In 8 patients, the numbness occurred after repeat GKS and was described as mild but not bothersome. Three patients categorized the numbness as somewhat or very bothersome. Nine of 11 patients with facial numbness were pain free without medication, whereas only 4 of 19 patients without numbness reported experiencing no pain (p = 0.0012). No patient experienced onset of any other cranial neuropathy or deafferentation pain. There was a significant correlation between the total dose of radiation and facial numbness. The cutoff value for facial numbness was 115-120 Gy; at this level or below, there was only 1 of 7 patients with facial numbness, whereas at above 120 Gy, 10 of 23 patients had facial numbness (p = 0.037).
Discussion
Pain Outcome After GKS for Recurrent TN
Successful pain control following GKS in cases of recurrent TN after a failed initial procedure occurs in approximately 65% of cases, which is worse than outcomes following most initial GKSs. 3, 7, 8, 10 There was no significant difference in pain relief after GKS in the 3 groups we evaluated, but there was a tendency for more pain relief in patients whose initial treatment was MVD surgery. For assessments of pain outcome, recurrent TN groups are usually compared with initial TN groups; however, in this study, we analyzed outcomes according to the various initial treatment modalities.
In earlier studies, most research showed that a previous procedure before GKS is or tends to be a prognostic factor, but this finding is controversial (Table 2) . 3, 11, 14, 16, 21, 26 According to Kondziolka et al., 11 patients who have not undergone previous surgery tend to have better outcomes (p = 0.14) than those who have, although this finding was not significant. However, those authors also demonstrated that differences in outcome were not dependent on the type of previous surgery for TN. Sheehan et al. 21 noted similar results-there was no difference between the individual groups they reviewed: MVD, glycerol injection, and neurectomy.
In our study, we also found similar results; however, we included all patients with recurrent TN for the comparison and not just those who initially underwent PRR or MVD but also patients who initially underwent GKS. The possible reason for this controversial finding could be associated with the variable causes underlying the recurrent TN that appears following an initial MVD. Microvascular decompression is not an ablative procedure, and the compressive effect may still be found in as many as 83% of repeated operations for recurrent TN after MVD. 25 Theoretically, MVD is a pathophysiological method that does not damage nerve fibers as do the other 2 procedures, which are ablative. The percentages of patients in whom neurovascular conflict or Teflon-induced changes have been found at a second surgery have been reported to range from 48% to 83%, and there have been some reports that patients in whom offending blood vessels are seen on MR images attain a favorable pain outcome. 4 Tawk et al. 24 reported that a previous ablative procedure was a predictor of a poor response to GKS (p = 0.012, OR = 14), and they also noted that patients who underwent 2 or more previous surgical procedures, including MVD, had a poor response. On the other hand, the percentages of cases in which there are no abnormalities from repeated posterior fossa exploration could be as high as 52% and that might play a role in the equivocal results. 1, 6, 12, 17, 25 Little et al. 13 reported that patients with a history of pain recurrence following MVD tended to respond poorly to GKS, but their results referred to freedom from pain and not just to pain control. In patients such as these, atypical features or multiple sclerosis could be related to this response. 4, 14, 26 Other factors associated with pain response to GKS include an isocenter closer to the brainstem, 3 a higher radiation dose, 16 and no previous surgery.
3,14
The recurrence rate for TN in our initial MVD group that later underwent GKS was 26%, which is comparable to other repeated operation groups of patients who underwent MVD (19%-30%) ( Table 3 ). In a study of 19 patients who required retreatment after an initial MVD, SanchezMejia et al. 20 also reported that radiosurgery was the final treatment in 72.2% of patients. We recommend GKS to be an effective method of treatment for patients with recurrent TN who have already undergone MVD.
Complications of GKS for Recurrent TN
Facial numbness is the most common side effect after any neurosurgical treatment. There was no significant difference among the 3 groups for facial numbness, but there was a tendency toward lower morbidity rates for the initial MVD and initial PRR groups. Facial numbness is a reasonable result of repeated GKS because the total radiation dose produces a much higher total dose to the target. Previous reports showed that facial numbness occurred in 11%-58% of patients. 8, 9, 15, 22 Our previous study showed a higher rate of facial numbness in patients following repeated GKS than in patients following initial GKS (p = 0.007), 10 so if the first procedure is either MVD or PRR, some changes in the threshold of the radiation effect may cause facial sensation. For recurrent TN in the MVD group, the first MVD procedure may alter the threshold of radiation tolerance, and when no abnormalities are found in the repeat MVD, this might mean there has been a demyelination change in the trigeminal nerve, which eventually will affect facial numbness. For this group of patients, GKS may be a better choice, because traditional repeated open surgery involves a trigeminal neurectomy, which will eventually cause facial numbness. Cho et al. 6 reported that 52% of patients who underwent partial sensory rhizotomy did not experience any abnormalities.
Further Salvage Procedures for a Failed Second Procedure Involving GKS
Eight patients had recurrent or residual pain after repeated GKS. All 8 of these patients underwent MVD, and 7 of them were pain free after these procedures. One patient in whom no offending blood vessels were observed during surgery did not become free from pain. Two of the patients later developed facial numbness, which is considered a side effect of radiation treatment. One patient underwent a third GKS, after which pain was relieved.
Twelve patients with recurrent TN underwent repeated GKS for pain control. Eight had successful pain management, but in 4 patients the repeated treatment failed.
To minimize facial numbness in patients who are still potential candidates for MVD, a total dose of ≤ 120 Gy should be considered. Microvascular decompression could be the last salvage procedure for failed repeated GKS. For failed initial MVD or PRR groups, we suggest a total dose of > 120 Gy for a better chance of pain relief if repeated GKS is considered. Nevertheless, the size of our series is modest, and relatively small numbers of patients were divided into groups; thus, more data are needed to confirm our results.
Conclusions
Gamma Knife surgery for residual or recurrent TN after an initial procedure is an acceptable treatment. The initial procedure may not be a factor affecting GKS results. Repeat GKS can still be considered in patients in whom GKS has failed, but we found a higher rate of numbness in patients who initially underwent GKS. Further salvage surgery using MVD is still a good method of management for repeated GKS, so we suggest that a total dose of ≤ 120 Gy can be considered for patients who are potential candidates for MVD. As for salvage surgery for recurrent TN in patients in whom an initial MVD or PRR has failed, a total dose of > 120 Gy could be considered. Regardless, it is important to note that the size of our series is modest, and more data are needed to verify our results.
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